Publications by authors named "Bert Bernard"

Claim this Profile
B
Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA(0),Tyr(3)]octreotate.
Flavio Forrer, Eric P Krenning, Peter P Kooij, Bert F Bernard, Mark Konijnenberg

Eur J Nucl Med Mol Imaging· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Renal uptake and retention of radiolabeled somatostatin, bombesin, neurotensin, minigastrin and CCK analogues: species and gender differences.
Marleen Melis, Eric P Krenning, Bert F Bernard, Monique de Visser, Edgar Rolleman

Nucl Med Biol· August 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Five Stabilized 111In-labeled neurotensin analogs in nude mice bearing HT29 tumors.
Paul J J M Janssen, Moniaue de Visser, Suzanne M Verwijnen, Bert F Bernard, Ananth Srinivasan

Cancer Biother Radiopharm· June 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate.
Edgar J Rolleman, Flavio Forrer, Bert Bernard, Magda Bijster, Marcel Vermeij

Eur J Nucl Med Mol Imaging· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term toxicity of [(177)Lu-DOTA (0),Tyr (3)]octreotate in rats.
Edgar J Rolleman, Eric P Krenning, Bert F Bernard, Monique de Visser, Magda Bijster

Eur J Nucl Med Mol Imaging· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From outside to inside? Dose-dependent renal tubular damage after high-dose peptide receptor radionuclide therapy in rats measured with in vivo (99m)Tc-DMSA-SPECT and molecular imaging.
Flavio Forrer, Edgar Rolleman, Magda Bijster, Marleen Melis, Bert Bernard

Cancer Biother Radiopharm· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Diagnostic versus therapeutic doses of [(177)Lu-DOTA-Tyr(3)]-octreotate: uptake and dosimetry in somatostatin receptor-positive tumors and normal organs.
Cristina Müller, Flavio Forrer, Bert F Bernard, Marleen Melis, Mark Konijnenberg

Cancer Biother Radiopharm· February 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[(99m)Tc]Demotate 2 in the detection of sst(2)-positive tumours: a preclinical comparison with [(111)In]DOTA-tate.
Theodosia Maina, Berthold A Nock, Paul Cordopatis, Bert F Bernard, Wout A P Breeman

Eur J Nucl Med Mol Imaging· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anticancer activity of targeted proapoptotic peptides.
Astrid Capello, Eric P Krenning, Bert F Bernard, Wout A P Breeman, Jack L Erion

J Nucl Med· January 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
1
111In-labelled somatostatin analogues in a rat tumour model: somatostatin receptor status and effects of peptide receptor radionuclide therapy.
Astrid Capello, Eric Krenning, Bert Bernard, Jean-Claude Reubi, Wout Breeman

Eur J Nucl Med Mol Imaging· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Localisation and mechanism of renal retention of radiolabelled somatostatin analogues.
Marleen Melis, Eric P Krenning, Bert F Bernard, Raffaella Barone, Theo J Visser

Eur J Nucl Med Mol Imaging· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Megalin is essential for renal proximal tubule reabsorption of (111)In-DTPA-octreotide.
Marion de Jong, Raffaella Barone, Eric Krenning, Bert Bernard, Marleen Melis

J Nucl Med· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiolabelling DOTA-peptides with 68Ga.
Wouter A P Breeman, Marion de Jong, Erik de Blois, Bert F Bernard, Mark Konijnenberg

Eur J Nucl Med Mol Imaging· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combination radionuclide therapy using 177Lu- and 90Y-labeled somatostatin analogs.
Marion de Jong, Wout A P Breeman, Roelf Valkema, Bert F Bernard, Eric P Krenning

J Nucl Med· January 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Norharman and alcohol-dependency in male Wistar rats.
Durk Fekkes, Bert F Bernard, Susanne L T Cappendijk

Eur Neuropsychopharmacol· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog.
Astrid Capello, Eric P Krenning, Bert F Bernard, Wout A P Breeman, Martin P van Hagen

J Nucl Med· October 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reduction of skeletal accumulation of radioactivity by co-injection of DTPA in [90Y-DOTA0,Tyr3]octreotide solutions containing free 90Y3+.
Wouter A P Breeman, Maarten Th M De Jong, Erik De Blois, Bert F Bernard, Marion De Jong

Nucl Med Biol· August 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Low-dose-rate irradiation by 131I versus high-dose-rate external-beam irradiation in the rat pancreatic tumor cell line CA20948.
Suzanne Verwijnen, Astrid Capello, Bert Bernard, Gerard van den Aardweg, Mark Konijnenberg

Cancer Biother Radiopharm· June 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radionuclide tumour therapy with ultrasound contrast microbubbles.
Annemieke van Wamel, Ayache Bouakaz, Bert Bernard, Folkert ten Cate, Nico de Jong

Ultrasonics· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Uptake of [111In-DTPA0]octreotide in the rat kidney is inhibited by colchicine and not by fructose.
Edgar J Rolleman, Eric P Krenning, Arthur Van Gameren, Bert F Bernard, Marion De Jong

J Nucl Med· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.
Bert Bernard, Astrid Capello, Martin van Hagen, Wout Breeman, Ananth Srinivasan

Cancer Biother Radiopharm· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
DOTA-NOC, a high-affinity ligand of somatostatin receptor subtypes 2, 3 and 5 for labelling with various radiometals.
Damian Wild, Jörg S Schmitt, Mihaela Ginj, Helmut R Mäcke, Bert F Bernard

Eur J Nucl Med Mol Imaging· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tyr3-octreotide and Tyr3-octreotate radiolabeled with 177Lu or 90Y: peptide receptor radionuclide therapy results in vitro.
Astrid Capello, Eric P Krenning, Wout A P Breeman, Bert F Bernard, Mark W Konijnenberg

Cancer Biother Radiopharm· October 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Anti-tumor effect and increased survival after treatment with [177Lu-DOTA0,Tyr3]octreotate in a rat liver micrometastases model.
Wouter A P Breeman, Amir Mearadji, Astrid Capello, Bert F Bernard, Casper H J van Eijck

Int J Cancer· April 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The addition of DTPA to [177Lu-DOTA0,Tyr3]octreotate prior to administration reduces rat skeleton uptake of radioactivity.
Wouter A P Breeman, Katy van der Wansem, Bert F Bernard, Arthur van Gameren, Jack L Erion

Eur J Nucl Med Mol Imaging· February 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis